Fentanyl Screen, Random, Urine
Use
Screening for drug abuse or use involving fentanyl. The assay is designed to have a high true-negative rate under CLIA conditions; however, as with all immunoassays, false positives may occur due to cross-reactivity and false negatives can occur due to antibody specificity limitations. The screen utilizes a competitive homogeneous enzyme immunoassay to detect fentanyl at a cutoff of 2 ng/mL in urine. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/63060?utm_source=openai))
Special Instructions
Not provided.
Limitations
This is a screening immunoassay, not a definitive confirmatory test. As such, it may produce false-positive results due to cross-reactivity with structurally similar compounds and false-negative results due to limited antibody cross-reactivity with certain fentanyl analogs. No confirmation is automatically performed. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/63060?utm_source=openai))
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 59673-4 - fentaNYL Ur Ql Scn
- 59673-4 - fentaNYL Ur Ql Scn
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
2 mL
Minimum Volume
0.5 mL
Container
Clean, plastic urine collection container; Submission in 5‑mL plastic tube (Sarstedt Aliquot Tube, 5 mL T914)
Collection Instructions
Collect a random urine specimen; No preservative.
Causes for Rejection
Specimen suitability evaluated at Mayo Clinic Laboratories; unspecified deficiencies may cause rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |